A Clinical registry study of Liao-Shi-Hua-Feng-Dan for stroke

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Conform to the diagnostic criteria for acute ischemic stroke in the Chinese guidelines for diagnosis and treatment of acute Ischemic Stroke 2018, or conform to the diagnostic criteria for cerebral hemorrhage in the Chinese guidelines for diagnosis and treatment of acute intracerebral hemorrhage 2019. Conform to the Diagnostic Efficacy Assessment Criteria for Stroke in 1995.
•2. The enrolled patients were hospitalized;
•3. The enrolled patients were patients with limb pain after stroke or numbness of limbs after stroke or limb spasms after stroke, and patients treated with Hua Fengdan;
•4. The patient gives informed consent and signs the informed consent form.

•1. Those who are allergic to the drug
•2. Those with combined serious diseases of liver, kidney, hematopoietic system, endocrine system and osteoarthrosis, psychiatric disease.
•3. Subjects who have difficulty cooperating to complete the neurological function and other assessments related to this study,or the clinical investigator judges that it is difficult for subjects to complete the evaluation and follow-up for other reasons.

发起方

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine